Skip to content
NBlaz – Lifestyle
Author:
Callio Therapeutics
Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer
September 28, 2026
Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer
September 9, 2026
Callio Therapeutics to Present Phase 1 Trial Design of CLIO-8221, Novel Dual-Payload ADC, at ASCO 2026
May 27, 2026
Callio Therapeutics to Present Poster on CLIO-8221, a Novel Dual-Payload Antibody-Drug Conjugate, at AACR 2026
April 15, 2026